Table 1

Demographic and clinical characteristics of patients

Overall cohort
(n=220)
No NAFLD
(n=69)
NAFLD
(n=151)
P values between NAFLD and no NAFLD
Age, years58±960±957±90.013
Gender, male %8386820.53
Ethnicity, n (%)<0.001
 Caucasian131 (60)44 (64)87 (58)
 Hispanic64 (29)9 (13)55 (36)
 African-American24 (11)16 (23)8 (5)
 Other1 (0)0 (0)1 (1)
Weight, kg101±1697±16104±160.004
Body mass index, kg/m2 33.7±4.831.5±4.534.7±4.6<0.001
Total body fat, %36±734±736±70.047
Hemoglobin A1c, %7.1±1.27.0±1.37.1±1.10.71
Fasting plasma glucose, mg/mL147±44146±48148±420.82
Fasting plasma insulin, μU/mL15±119±717±12<0.001
HOMA-IR5.5±4.93.2±3.16.4±5.2<0.001
Adipo-IRindex, mmol/L×μU/mL6.7±6.53.2±3.58.1±6.9<0.001
Matsuda index3.4±3.22.5±1.62.5±1.6<0.001
Diabetes medications
 Metformin, %7476730.70
 Sulfonylurea, %4241420.86
 Insulin, %2431220.19
Intrahepatic triglyceride content, %10±83±115±8<0.001
Aspartate aminotransferase, U/L36±2424±1141±26<0.001
Alanine aminotransferase, U/L47±3726±1857±39<0.001
Cytokeratin-18 fragments, U/L290±303136±123360±334<0.001
Biopsy performed, n (%)0 (0%)151 (100%)
Patients with NASH, n (%)96 (64%)
Patients with NAFLD activity score≥4, n (%)92 (61%)
Patients with advanced fibrosis, n (%)25 (17%)
NAFLD activity score3.9±1.6
0/1/2/3/4/5/6/7/80/0/29/31/28/33/24/5/1
Steatosis grade1.7±0.8
S0/S1/S2/S3, n0/61/60/30
Inflammation grade1.4±0.6
I0/I1/I2/I3, n1/77/69/4
Ballooning grade0.7±0.7
B0/B1/B2, n55/75/21
Fibrosis stage1.2±1.1
F0/F1/F2/F3/F4, n38/63/25/19/6
  • HOMA-IR, NAFLD, NASH.